Please assess the completion status of the following clinical trial:

Trial Title: Masitinib in Patients With Mild to Moderate Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria include:~1. Patient with dementia of Alzheimer's type, according to the Diagnostic and Statistical Manual of Mental Disorders criteria (DSM-IV)~2. Patient with probable Alzheimer' disease according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association criteria (NINCDS-ADRDA)~3. Patient with MMSE ≥ 12 and ≤ 25 at baseline~4. Patient treated for a minimum of 6 months with a stable dose of cholinesterase inhibitors (donepezil, rivastigmine or galantamine) at baseline, and/or a stable dose of memantine for a minimum of 6 months at baseline, with no changes foreseen in therapy throughout the study.~Exclusion criteria include:~1. Patient with any other cause of dementia not due to Alzheimer's disease.~2. Patient with Alzheimer disease with severe forms of delusions or delirium (patients with light and mild forms of delusions and delirium will be allowed in the study).

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Masitinib escalating dose (Type: EXPERIMENTAL): Participants receive masitinib at 4.5 mg/kg/day, given orally twice daily, with a dose escalation to 6 mg/kg/day after 3 months of treatment
- Masitinib fixed dose (4.5 mg/kg/day) (Type: EXPERIMENTAL): Participants receive masitinib at 4.5 mg/kg/day, given orally twice daily.
- Masitinib fixed dose (3.0 mg/kg/day) (Type: EXPERIMENTAL): Participants receive masitinib at 3.0 mg/kg/day, given orally twice daily.
- Placebo (escalating dose) (Type: PLACEBO_COMPARATOR): Participants receive placebo, given orally twice daily, with a matched dose escalation after 3 months of treatment
- Placebo (fixed dose) (Type: PLACEBO_COMPARATOR): Participants receive fixed dose placebo, given orally twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).